Back to discover
Disease

Infant, Newborn, Diseases

Late-stage therapeutic developmentEmerging research
2
Publications
10
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

CLPB Deficiency Associated Neonatal Cavitating Leukoencephalopathy: A Potential Pathomechanism Underlying Neurologic Disorder.

Research2023-10-30Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q4 2026.
Major developments
Upcoming trial readoutImportant
Results expected Q4 20262025-11-20
Clinical Milestones1View
Activity timeline1

Clinical trials

6 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
10
All trials
2
Active
5
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20232024
Most influential

CLPB Deficiency Associated Neonatal Cavitating Leukoencephalopathy: A Potential Pathomechanism Underlying Neurologic Disorder.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society · 2024 · 2 cites
Recent publications

CLPB Deficiency Associated Neonatal Cavitating Leukoencephalopathy: A Potential Pathomechanism Underlying Neurologic Disorder.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society · 2024 · 2 cites
Major themes4
  • Infant, Newborn, Diseases2
  • Chemokine CX3CL11
  • Endopeptidase Clp1
  • Leukoencephalopathies1
Leading journals2
  • Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society1
  • Stroke1
Leading researchers8
  • Bellamine H1
  • Chen X1
  • Darouich S1
  • Dong S1
  • Flores JJ1
  • Gtari D1
  • Han M1
  • He Q1
Affiliations (unnormalised)6
  • Department of Neurosurgery and Brain and Nerve Research Laboratory (Y.Z.)1
  • First Affiliated Hospital of Soochow University1
  • Institut Supérieur des Sciences Humaines de Tunis1
  • Institute for Fetology (P.Z.)1
  • Loma Linda University School of Medicine1
  • School of Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.